Misonix Supports Uganda Spine Surgery Mission For The Fourth Consecutive Year

Aug 13, 2015, 12:55 ET from Misonix, Inc.

FARMINGDALE, N.Y., Aug. 13, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, neurosurgery, wound debridement, laparoscopic surgery and other surgical applications, announces its annual support for the Uganda Spine Surgery Mission organized by leading spine surgeon Isador Lieberman, MD from the Texas Back Institute in Plano, TX.

"Again this year, Misonix has been generous to the Uganda Spine Surgery Mission, and with their help, many less fortunate individuals will be able to return to an active and healthy spine life," said Dr. Lieberman.

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix commented, "We are proud to support the Uganda Spine Surgery Mission and the dedicated surgeons committed to improving patient lives. With the BoneScalpel® these surgeons have been able to perform spine surgery that is safe and efficient. We want to thank Dr. Lieberman, the mission's many spine surgeons and medical staff for their charitable work in Uganda. Their efforts to help the less fortunate are inspirational."

The Uganda Spine Surgery Mission (www.ugandaspinesurgerymission.com) was founded in 2006 by Dr. Mark Kayanja (originally from Uganda) and Dr. Lieberman with the purpose of providing advanced spine care to Ugandan patients afflicted by infectious, degenerative, traumatic and congenital spinal ailments. This year's mission treated 60 spine surgery patients. The mission's surgical team included three long-time BoneScalpel users: Dr. Lieberman, Dr. Paul Holman from Methodist Hospital Houston in Houston, TX and Dr. Shane Burch from UCSF Medical Center in San Francisco, CA.  

This is the fourth consecutive year that Misonix provided support for this mission. The spine surgeons that operated in Uganda valued the BoneScalpel as it provided clinical and surgical efficiencies by reducing blood loss, the need for blood transfusions and operating time. The BoneScalpel is also soft tissue sparring and can be used safely around important structures, like the dura and nerves.

Dr. Burch explained, "The patients we treated in Uganda included both children and adults with complex and advanced spinal deformities. To correct these pathologies, many extensive osteotomies were surgically performed. By using the BoneScalpel to perform these osteotomies, we improve the autogenous bone graft that is harvested while reducing the surgical time required to complete each procedure. Both are important measures to reduce to ensure good clinical outcomes."

Dr. Holman added, "The BoneScalpel is an important part of my surgical practice as it is more efficient than traditional tools, reduces blood loss and provides large amounts of bone graft for use elsewhere during the procedure."

Mr. McManus, Jr., concluded, "This mission highlights the clinical and economic importance of the BoneScalpel in spine surgery. Surgeons around the world are rapidly adopting the BoneScalpel into their surgical practice."

About Misonix Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contacts:

Misonix Contact:

Lytham Partners, LLC

Richard Zaremba

Robert Blum, Joe Dorame, Joe Diaz

631-694-9555

602-889-9700

invest@misonix.com 

mson@lythampartners.com

 

SOURCE Misonix, Inc.



RELATED LINKS

http://www.misonix.com